|Bid||11.26 x 1100|
|Ask||14.00 x 3200|
|Day's Range||12.33 - 12.81|
|52 Week Range||8.01 - 28.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.67|
Subscribe to Yahoo Finance Plus to view Fair Value for FHTXLearn more
Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Viewing insider transactions for Foghorn Therapeutics Inc.'s ( NASDAQ:FHTX ) over the last year, we see that insiders...
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences. Events: Morgan Stanley Virtual Annual Global Healthcare ConferenceFormat: Fireside Chat and investor 1x1 meetingsThursday, September 9